Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592552 | 0.90 | HDAC1 (0.46) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL8246236 | 0.89 | RAB9A (0.51) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL13316890 | 0.86 | HDAC6 (0.50) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL8250477 | 0.86 | RAB9A (0.51) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL8248244 | 0.85 | HDAC6 (0.64) | HDAC1RAB9ANPC1HDAC2HPGD | |
| SCHEMBL5593007 | 0.83 | RAB9A (0.48) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL5593004 | 0.83 | RAB9A (0.48) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL8248413 | 0.83 | HDAC1 (0.55) | HDAC1RAB9ANPC1HDAC2HPGD | |
| SCHEMBL3615851 | 0.82 | LMNA (0.51) | HDAC1RAB9ANPC1POLBHDAC2 | |
| SCHEMBL8249138 | 0.82 | RAB9A (0.48) | HDAC1RAB9ANPC1POLBHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | HDAC1 307/4885RAB9A 601/4885NPC1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.